title: [Effect of topical carbonic anhydrase inhibitor (MK-507) on intraocular pressure of normal human eyes].
abstract: The effects of topical carbonic anhydrase inhibitor (MK-507) on intraocular pressure (IOP) were studied in normal human eyes. The subjects were 6 normal volunteers. As a base line study, IOP and aqueous protein concentration determined by laser flare-cell photometry were examined from 0900 to 1800 hours. Then, the same time-course examinations were performed in the same subjects with an instillation of 1% MK-507 or administration of acetazolamide at a dose of 250 mg on different days. MK-507 decreased IOP 2 hours after the instillation, and showed maximum reduction of IOP at 3 hours. MK-507 increased aqueous protein concentration 2 hours after the instillation, and reached its maximum concentration at 4 hours. Acetazolamide decreased IOP and increased aqueous protein concentration 1 hours after the administration. Maximum decrease of IOP was obtained at 1 hour after the administration of acetazolamide. An increase in aqueous protein concentration occurred at 1 hour after the administration, but its maximum increase was at 3 hours. Corneal thickness, anterior chamber depth, anterior chamber volume, and serum protein concentration were not affected by either drug treatment. These results suggest that the inhibition of aqueous humor formation causes the reduction of IOP seen in the use of MK-507.
authors.affiliation: Department of Ophthalmology, Nihon University School of Medicine, Tokyo, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Yamazaki
authors.forename: S
authors.initials: S
authors.lastname: Miyamoto
authors.forename: M
authors.initials: M
authors.lastname: Sawa
mesh_terms: D000086:Acetazolamide / Q000494:pharmacology; D000287:Administration, Topical; D000328:Adult; D001082:Aqueous Humor / Q000187:drug effects / Q000378:metabolism; D002257:Carbonic Anhydrase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D003864:Depression, Chemical; D005136:Eye Proteins / Q000378:metabolism; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D013449:Sulfonamides / Q000008:administration & dosage / Q000494:pharmacology*; D013876:Thiophenes / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D002257:Carbonic Anhydrase Inhibitors; D005136:Eye Proteins; D013449:Sulfonamides; D013876:Thiophenes; C062765:dorzolamide; D000086:Acetazolamide